AstraZeneca Seeks Cmte. Input On Further Iressa Marketing Steps
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca publishing "Dear Doctor" letter on failed survival study results in oncology journals for foreseeable future. Efforts to inform physicians of trial results have led to a "substantial reduction" in new prescriptions for gefitinib, company says.
You may also be interested in...
Public Citizen Seeks Iressa Withdrawal From Market
Public Citizen's Health Research Group is calling for FDA to withdraw licensure of AstraZeneca's epidermal growth factor receptor inhibitor Iressa
Public Citizen Seeks Iressa Withdrawal From Market
Public Citizen's Health Research Group is calling for FDA to withdraw licensure of AstraZeneca's epidermal growth factor receptor inhibitor Iressa
Bisphosphonate Osteonecrosis May Be Class Effect, FDA Safety Review Says
ODS review finds 139 cases of osteonecrosis in patients receiving IV bisphosphonates Zometa and Aredia, or oral drugs Fosamax and Actonel, although many fewer are found with oral drugs vs. IV. Zometa and Aredia are subject of March 4 oncologic drugs advisory committee meeting on osteonecrosis of the jaw.